CTRI/2020/11/029305尚未招募未知
Clarithromycin in post Covid parenchymal organizing pneumonia - an open labelled randomized control trial - PCOVID
SELF DrIrfan Ismail Ayub0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. All patients diagnosed with COVID 19 based on positive result on SARS-CoV2 RT-PCR or CBNAAT from nasopharyngeal or oropharyngeal swab or secretions.
- •2. More than two weeks, but less than six weeks have lapsed after the above diagnostic positive result.
- •3. A repeat nasopharyngeal or oropharyngeal swab test (either SARS-CoV2 RT-PCR or CBNAAT) performed at two weeks or later, after earlier positive result, is now negative.
- •4. CT scan of thorax performed after two weeks and less than six weeks after the first positive result, shows features of organizing pneumonia.
- •Organizing pneumonia on CT scan of thorax is diagnosed when, one or more of the following features are identified on the CT scan images of thorax:
- •1.Unilateral or bilateral basal subpleural lobar, segmental or perilobular consolidation
- •2.Halo sign
- •3.Reverse halo sign or atoll sign
- •4.Target sign or bulls-eye sign or double halo sign
排除标准
- •1.Patient is unwilling to provide consent
- •2.Patients with preexisting parenchymal or interstitial lung disease
研究者
相似试验
招募中
不适用
inezolid and clarithromycin drug-interaction study in multidrug-resistant and extensively drug-resistant tuberculosis patients.-'drug interaction'- linezolid- clarithromycin- multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB)in dutch/ in het nederlands:- geneesmiddelinteractie- linezolid- claritromycine- multidrug-resistente and extensieve drug-resistente tuberculose (MDR/XDR-TBC)NL-OMON24566niversity Medical Center GroningenA.t.t.n. Prof Dr JGW Kosterink, Department of Hospital and Clinical PharmacyP.O. Box 30.001; 9700 RB Groningen,The NetherlandsTel: +31 50 361 4071Fax: +31 50 361 4087Email: j.g.w.kosterink@umcg.nl7
已完成
不适用
Clarithromycin plus intravenous immunoglobulin therapy for Kawasaki disease, a phase 3, multicenter, randomized, double blind, placebo control study.Kawasaki diseaseJPRN-UMIN000024311Clinical Research Support Center Kyushu250
已完成
不适用
CAM (Clarithromycin) Effectivity for COVID-19 pneumonia which does not require oxygen administration; multicenter, randomized-controlled, open-label, 3-armed parallel group comparison, exploratory trialCOVID-19 pneumonia which does not require oxygen administrationCOVID-19, Clarith, Clarithromycin, Macrolide antimicrobial agentsJPRN-jRCTs071210011Mukae Hiroshi60
已完成
Unknown
Therapeutic Effects of Clarithromycin and Molnupiravir in Management of COVID-19 PatientsJPRN-UMIN000048841Daido Central Hospital119
已完成
不适用
Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial.pneumoniaJPRN-UMIN000023355Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine200